[Phosphodiesterase inhibitors].
Phosphodiesterase III inhibitors constitute a new therapeutic group for congestive cardiac failure. They inhibit the degradation of cyclic adenosine monophosphate and increase the intracellular calcium. They have a double inotropic and vasodilator haemodynamics occurs without any increase in the myocardial effect. The improvement in the consumption of oxygen. The beneficial haemodynamic effect seems to last over a medium period of time, but the survival in the long term treatment is not yet known.
Sarkis
A
A
Service de Cardiologie, Hôpital Saint-Joseph, Paris.
Pornin
M
M
D004594:Electrophysiology; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
D010726:Phosphodiesterase Inhibitors
Les inhibiteurs des phosphodiestérases.